iSpecimen Inc(ISPC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -50.28 | Insider Own | - | Shs Outstand | 2.5M | Perf Week | -9.15% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.5M | Perf Month | -27.93% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 2.25% | Short Float | 6.3% | Perf Quarter | -54.1% |
| Income | -0.01B | P/S | 4.68 | EPS this Y | - | Inst Trans | 0.05% | Short Ratio | 0.24 | Perf Half Y | -80.88% |
| Sales | 0.00B | P/B | 0.76 | EPS next 5Y | - | ROA | -170.1% | Short Interest | 0.16M | Perf YTD | -91.62% |
| Book/sh | 1.14 | P/C | 0.5 | EPS past 3/5Y | 53.84% 30.62% | ROE | -968.47% | 52W High | -97.49% ($34.80) | Perf Year | -97.39% |
| Cash/sh | 1.75 | P/FCF | - | Sales past 3/5Y | -42.97% -25.1% | ROIC | -596% | 52W Low | 10.59% ($0.79) | Perf 3Y | -99.83% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 86.78% | Gross Margin | -355.95% | Volatility(W/M) | 7.84% 7.38% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | -4.19 | Sales Y/Y TTM | -92.11% | Oper. Margin | -2020.04% | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.82 | EPS Q/Q | 94.17% | Profit Margin | -2449.04% | RSI (14) | 30.49 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.82 | Sales Q/Q | -78.69% | SMA20 | -13.19% ($1) | Beta | 1.52 | Target Price | $2400 |
| Payout | - | Debt/Eq | 0.14 | Earnings | - | SMA50 | -33.95% ($1.32) | Rel Volume | 0.07 | Prev Close | $0.84 |
| Employees | 7 | LT Debt/Eq | 0.1 | EPS/Sales Surpr. | - | SMA200 | -82.7% ($5.03) | Avg Volume(3M) | 0.66M | Price | $0.87 |
| IPO | 2021/6/17 | Option/Short | No/Yes | Trades | 145 | Volume | 49,120 | Change | 3.85% |
A U.S. micro-cap company that operates a digital marketplace connecting human biospecimens (blood, tissue, cells, and other biological samples) and clinical data with life science researchers. It maintains a network of hospitals, research institutions, and biospecimen providers, and has recently announced a Solana blockchain-based digital asset treasury strategy as well.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 7% of its average volume.
ISPC has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $468. Peers typically go for $451.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #44 of 44 in the industry
Based on market cap of $2M.
FAQ
What kind of company is ISPC?
ISPC belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of ISPC?
The market cap of ISPC is approximately $2M, ranking 5,784 within its sector.
What is the 52-week high and low for ISPC?
ISPC has recorded a 52-week high of $34.80 and a low of $0.79.
